De-escalation of treatment in HER2-positive breast cancer: Determinants of response and mechanisms of resistance

Breast

Volumn 34, Issue , 2017, Pages S19-S26

  Veeraraghavan, Jamunarani ^a   De Angelis, Carmine ^a   Reis Filho, Jorge S ^b   Pascual, Tomás ^c   Prat, Aleix ^c   Rimawi, Mothaffar F ^a   Osborne, C Kent ^a   Schiff, Rachel ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c HOSPITAL CLÍNIC   (Spain)

Author keywords

Estrogen receptor; HER2 positive breast cancer; HER2 targeted therapy resistance; Oncogenic addiction; PI3K PTEN; Tumor microenvironment

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, HUMAN; LAPATINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; QUINAZOLINE DERIVATIVE; TRASTUZUMAB;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CLINICAL EFFECTIVENESS; CLINICAL OUTCOME; DOWN REGULATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; HER2 GENE; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; IMMUNE RESPONSE; MOLECULARLY TARGETED THERAPY; ONCOGENE ADDICTION; PI3K/AKT SIGNALING; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; BREAST TUMOR; DRUG RESISTANCE; FEMALE; GENETICS; IMMUNOLOGY; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; ONCOGENE ADDICTION; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; SIGNAL TRANSDUCTION; TRASTUZUMAB; TUMOR MICROENVIRONMENT;

EID: 85021792726     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2017.06.022     Document Type: Article

References (85)

1. Rimawi, M.F., Schiff, R., Osborne, C.K., Targeting HER2 for the treatment of breast cancer. Annu Rev Med 66 (2015), 111–128.
2. Gutierrez, C., Schiff, R., HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 135:1 (2011), 55–62.
3. Citri, A., Yarden, Y., EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:7 (2006), 505–516.
4. Baselga, J., Bradbury, I., Eidtmann, H., Di Cosimo, S., de Azambuja, E., Aura, C., et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 379:9816 (2012), 633–640.
5. Swain, S.M., Baselga, J., Kim, S.B., Ro, J., Semiglazov, V., Campone, M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 372:8 (2015), 724–734.
6. Rimawi, M.F., Wiechmann, L.S., Wang, Y.C., Huang, C., Migliaccio, I., Wu, M.F., et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res 17:6 (2011), 1351–1361.
7. Arpino, G., Gutierrez, C., Weiss, H., Rimawi, M., Massarweh, S., Bharwani, L., et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst 99:9 (2007), 694–705.
8. Wang, Y.C., Morrison, G., Gillihan, R., Guo, J., Ward, R.M., Fu, X., et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers–role of estrogen receptor and HER2 reactivation. Breast Cancer Res, 13(6), 2011, R121.
9. Gianni, L., Pienkowski, T., Im, Y.H., Roman, L., Tseng, L.M., Liu, M.C., et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 13:1 (2012), 25–32.
10. Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol 18(4):545–554.
11. Rimawi, M.F., Mayer, I.A., Forero, A., Nanda, R., Goetz, M.P., Rodriguez, A.A., et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006. J Clin Oncol 31:14 (2013), 1726–1731.
12. Rexer, B.N., Arteaga, C.L., Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications. Crit Rev Oncog 17:1 (2012), 1–16.
13. Tortora, G., Mechanisms of resistance to HER2 target therapy. J Natl Cancer Inst Monogr 2011:43 (2011), 95–98.
14. Kessler, E.R., Elias, A.D., Resistance to HER2-targeted therapy in HER2+ breast cancer. Clin Med Rev Women's Health 4:2 (2012), 15–26.
15. Puglisi, F., Minisini, A.M., De Angelis, C., Arpino, G., Overcoming treatment resistance in HER2-positive breast cancer: potential strategies. Drugs 72:9 (2012), 1175–1193.
16. Weinstein, I.B., Cancer. Addiction to oncogenes–the Achilles heal of cancer. Science 297:5578 (2002), 63–64.
17. Carey, L.A., Berry, D.A., Cirrincione, C.T., Barry, W.T., Pitcher, B.N., Harris, L.N., et al. Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol 34:6 (2016), 542–549.
18. Ng, C.K., Martelotto, L.G., Gauthier, A., Wen, H.C., Piscuoglio, S., Lim, R.S., et al. Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol, 16, 2015, 107.
19. Wolff, A.C., Hammond, M.E., Hicks, D.G., Dowsett, M., McShane, L.M., Allison, K.H., et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:31 (2013), 3997–4013.
20. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., et al. The cBio Cancer Genomics Portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2:5 (2012), 401–404.
21. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 6(269), 2013, pl1.
22. Bose, R., Kavuri, S.M., Searleman, A.C., Shen, W., Shen, D., Koboldt, D.C., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 3:2 (2013), 224–237.
23. Boulbes, D.R., Arold, S.T., Chauhan, G.B., Blachno, K.V., Deng, N., Chang, W.C., et al. HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer. Mol Oncol 9:3 (2015), 586–600.
24. Zuo, W.J., Jiang, Y.Z., Wang, Y.J., Xu, X.E., Hu, X., Liu, G.Y., et al. Dual characteristics of novel HER2 kinase domain mutations in response to HER2-targeted therapies in human breast cancer. Clin Cancer Res 22:19 (2016), 4859–4869.
25. Xu, X., De Angelis, C., Burke, K.A., Nardone, A., Hu, H., Qin, L., et al. HER2 reactivation through acquisition of the HER2 L755S mutation as a mechanism of acquired resistance to HER2-targeted therapy in HER2+ breast cancer. Clin Cancer Res, 2017.
26. Jeselsohn, R., Buchwalter, G., De Angelis, C., Brown, M., Schiff, R., ESR1 mutations-a mechanism for acquired endocrine resistance in breast cancer. Nat Rev Clin Oncol 12:10 (2015), 573–583.
27. Christianson, T.A., Doherty, J.K., Lin, Y.J., Ramsey, E.E., Holmes, R., Keenan, E.J., et al. NH2-terminally truncated HER-2/neu protein: relationship with shedding of the extracellular domain and with prognostic factors in breast cancer. Cancer Res 58:22 (1998), 5123–5129.
28. Molina, M.A., Codony-Servat, J., Albanell, J., Rojo, F., Arribas, J., Baselga, J., Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61:12 (2001), 4744–4749.
29. Molina, M.A., Saez, R., Ramsey, E.E., Garcia-Barchino, M.J., Rojo, F., Evans, A.J., et al. NH(2)-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin Cancer Res 8:2 (2002), 347–353.
30. Saez, R., Molina, M.A., Ramsey, E.E., Rojo, F., Keenan, E.J., Albanell, J., et al. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer. Clin Cancer Res 12:2 (2006), 424–431.
31. Scaltriti, M., Rojo, F., Ocana, A., Anido, J., Guzman, M., Cortes, J., et al. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Inst 99:8 (2007), 628–638.
32. Zhang, N., Chang, Y., Rios, A., An, Z., HER3/ErbB3, an emerging cancer therapeutic target. Acta Biochim Biophys Sin (Shanghai) 48:1 (2016), 39–48.
33. Vaz-Luis, I., Winer, E.P., Lin, N.U., Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?. Ann Oncol 24:2 (2013), 283–291.
34. Xia, W., Bacus, S., Hegde, P., Husain, I., Strum, J., Liu, L., et al. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer. Proc Natl Acad Sci U S A 103:20 (2006), 7795–7800.
35. Giuliano, M., Hu, H., Wang, Y.C., Fu, X., Nardone, A., Herrera, S., et al. Upregulation of ER signaling as an adaptive mechanism of cell survival in HER2-positive breast tumors treated with anti-HER2 therapy. Clin Cancer Res 21:17 (2015), 3995–4003.
36. Fumagalli, D., Venet, D., Ignatiadis, M., Azim, H.A. Jr., Maetens, M., Rothe, F., et al. RNA sequencing to predict response to neoadjuvant anti-HER2 therapy: a secondary analysis of the NeoALTTO randomized clinical trial. JAMA Oncol 3:2 (2016), 227–234.
37. Schneeweiss, A., Chia, S., Hickish, T., Harvey, V., Eniu, A., Hegg, R., et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:9 (2013), 2278–2284.
38. Untch, M., Loibl, S., Bischoff, J., Eidtmann, H., Kaufmann, M., Blohmer, J.U., et al. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol 13:2 (2012), 135–144.
39. Mayer, I.A., Arteaga, C.L., The PI3K/AKT pathway as a target for cancer treatment. Annu Rev Med 67 (2016), 11–28.
40. Fruman, D.A., Rommel, C., PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov 13:2 (2014), 140–156.
41. Fu, X., Creighton, C.J., Biswal, N.C., Kumar, V., Shea, M., Herrera, S., et al. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. Breast Cancer Res, 16(5), 2014, 430.
42. Berns, K., Horlings, H.M., Hennessy, B.T., Madiredjo, M., Hijmans, E.M., Beelen, K., et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:4 (2007), 395–402.
43. Eichhorn, P.J., Gili, M., Scaltriti, M., Serra, V., Guzman, M., Nijkamp, W., et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68:22 (2008), 9221–9230.
44. Chandarlapaty, S., Sakr, R.A., Giri, D., Patil, S., Heguy, A., Morrow, M., et al. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. Clin Cancer Res 18:24 (2012), 6784–6791.
45. Fujita, T., Doihara, H., Kawasaki, K., Takabatake, D., Takahashi, H., Washio, K., et al. PTEN activity could be a predictive marker of trastuzumab efficacy in the treatment of ErbB2-overexpressing breast cancer. Br J Cancer 94:2 (2006), 247–252.
46. O'Brien, N.A., Browne, B.C., Chow, L., Wang, Y., Ginther, C., Arboleda, J., et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9:6 (2010), 1489–1502.
47. Faratian, D., Goltsov, A., Lebedeva, G., Sorokin, A., Moodie, S., Mullen, P., et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res 69:16 (2009), 6713–6720.
48. Stemke-Hale, K., Gonzalez-Angulo, A.M., Lluch, A., Neve, R.M., Kuo, W.L., Davies, M., et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68:15 (2008), 6084–6091.
49. Pogue-Geile, K.L., Song, N., Jeong, J.H., Gavin, P.G., Kim, S.R., Blackmon, N.L., et al. Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. J Clin Oncol 33:12 (2015), 1340–1347.
50. Loi, S., Michiels, S., Lambrechts, D., Fumagalli, D., Claes, B., Kellokumpu-Lehtinen, P.L., et al. Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst 105:13 (2013), 960–967.
51. Loibl, S., Majewski, I., Guarneri, V., Nekljudova, V., Holmes, E., Bria, E., et al. PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab. Ann Oncol 27:8 (2016), 1519–1525.
52. Baselga, J., Cortes, J., Im, S.A., Clark, E., Ross, G., Kiermaier, A., et al. Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer. J Clin Oncol 32:33 (2014), 3753–3761.
53. Cizkova, M., Dujaric, M.E., Lehmann-Che, J., Scott, V., Tembo, O., Asselain, B., et al. Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. Br J Cancer 108:9 (2013), 1807–1809.
54. Jensen, J.D., Knoop, A., Laenkholm, A.V., Grauslund, M., Jensen, M.B., Santoni-Rugiu, E., et al. PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Ann Oncol 23:8 (2012), 2034–2042.
55. Nagata, Y., Lan, K.H., Zhou, X., Tan, M., Esteva, F.J., Sahin, A.A., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:2 (2004), 117–127.
56. Saal, L.H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X., et al. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65:7 (2005), 2554–2559.
57. Pandolfi, P.P., Breast cancer–loss of PTEN predicts resistance to treatment. N Engl J Med 351:22 (2004), 2337–2338.
58. Crowder, R.J., Lombardi, D.P., Ellis, M.J., Successful targeting of ErbB2 receptors-is PTEN the key?. Cancer Cell 6:2 (2004), 103–104.
59. Ingold Heppner, B., Untch, M., Denkert, C., Pfitzner, B.M., Lederer, B., Schmitt, W., et al. Tumor-infiltrating lymphocytes: a predictive and prognostic biomarker in neoadjuvant-treated HER2-positive breast cancer. Clin Cancer Res 22:23 (2016), 5747–5754.
60. Gallardo, A., Lerma, E., Escuin, D., Tibau, A., Munoz, J., Ojeda, B., et al. Increased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas. Br J Cancer 106:8 (2012), 1367–1373.
61. Esteva, F.J., Guo, H., Zhang, S., Santa-Maria, C., Stone, S., Lanchbury, J.S., et al. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177:4 (2010), 1647–1656.
62. Wang, L., Zhang, Q., Zhang, J., Sun, S., Guo, H., Jia, Z., et al. PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer, 11, 2011, 248.
63. Gori, S., Sidoni, A., Colozza, M., Ferri, I., Mameli, M.G., Fenocchio, D., et al. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol 20:4 (2009), 648–654.
64. Yonemori, K., Tsuta, K., Shimizu, C., Hatanaka, Y., Hirakawa, A., Ono, M., et al. Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. J Surg Oncol 101:3 (2010), 222–227.
65. Loi, S., Michiels, S., Salgado, R., Sirtaine, N., Jose, V., Fumagalli, D., et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol 25:8 (2014), 1544–1550.
66. Stern, H.M., Gardner, H., Burzykowski, T., Elatre, W., O'Brien, C., Lackner, M.R., et al. PTEN loss Is associated with worse outcome in HER2-amplified breast cancer patients but Is not associated with trastuzumab resistance. Clin Cancer Res 21:9 (2015), 2065–2074.
67. Park, Y.H., Jung, H.A., Choi, M.K., Chang, W., Choi, Y.L., Do, I.G., et al. Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment. Br J Cancer 110:2 (2014), 384–391.
68. Perez, E.A., Dueck, A.C., McCullough, A.E., Chen, B., Geiger, X.J., Jenkins, R.B., et al. Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol 31:17 (2013), 2115–2122.
69. Dave, B., Migliaccio, I., Gutierrez, M.C., Wu, M.F., Chamness, G.C., Wong, H., et al. Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol 29:2 (2011), 166–173.
70. Xia, W., Husain, I., Liu, L., Bacus, S., Saini, S., Spohn, J., et al. Lapatinib antitumor activity is not dependent upon phosphatase and tensin homologue deleted on chromosome 10 in ErbB2-overexpressing breast cancers. Cancer Res 67:3 (2007), 1170–1175.
71. Nuciforo, P.G., Aura, C., Holmes, E., Prudkin, L., Jimenez, J., Martinez, P., et al. Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status. Ann Oncol 26:7 (2015), 1494–1500.
72. Lu, Y., Yu, Q., Liu, J.H., Zhang, J., Wang, H., Koul, D., et al. Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades. J Biol Chem 278:41 (2003), 40057–40066.
73. Wang, S.E., Xiang, B., Zent, R., Quaranta, V., Pozzi, A., Arteaga, C.L., Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. Cancer Res 69:2 (2009), 475–482.
74. Liang, K., Esteva, F.J., Albarracin, C., Stemke-Hale, K., Lu, Y., Bianchini, G., et al. Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. Cancer Cell 18:5 (2010), 423–435.
75. Zhang, S., Huang, W.C., Li, P., Guo, H., Poh, S.B., Brady, S.W., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 17:4 (2011), 461–469.
76. Takeda, T., Yamamoto, H., Kanzaki, H., Suzawa, K., Yoshioka, T., Tomida, S., et al. Yes1 signaling mediates the resistance to Trastuzumab/Lapatinib in breast cancer. PLoS One, 12(2), 2017, e0171356.
77. Salgado, R., Denkert, C., Campbell, C., Savas, P., Nuciforo, P., Aura, C., et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with lapatinib and trastuzumab: a secondary analysis of the NeoALTTO trial. JAMA Oncol 1:4 (2015), 448–454.
78. Bianchini, G., Pusztai, L., Pienkowski, T., Im, Y.H., Bianchi, G.V., Tseng, L.M., et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol 26:12 (2015), 2429–2436.
79. Perez, E.A., Ballman, K.V., Tenner, K.S., Thompson, E.A., Badve, S.S., Bailey, H., et al. Association of stromal tumor-infiltrating lymphocytes with recurrence-free survival in the N9831 adjuvant trial in patients with early-stage HER2-positive breast cancer. JAMA Oncol 2:1 (2016), 56–64.
80. Perez, E.A., Thompson, E.A., Ballman, K.V., Anderson, S.K., Asmann, Y.W., Kalari, K.R., et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group N9831 adjuvant trastuzumab trial. J Clin Oncol 33:7 (2015), 701–708.
81. Dieci, M.V., Prat, A., Tagliafico, E., Pare, L., Ficarra, G., Bisagni, G., et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol 27:10 (2016), 1867–1873.
82. Denkert, C., von Minckwitz, G., Brase, J.C., Sinn, B.V., Gade, S., Kronenwett, R., et al. Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers. J Clin Oncol 33:9 (2015), 983–991.
83. Luen, S.J., Salgado, R., Fox, S., Savas, P., Eng-Wong, J., Clark, E., et al. Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: a retrospective analysis of the CLEOPATRA study. Lancet Oncol 18:1 (2017), 52–62.
84. Tolaney, S.M., Barry, W.T., Dang, C.T., Yardley, D.A., Moy, B., Marcom, P.K., et al. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med 372:2 (2015), 134–141.
85. TBCRC023: a randomized multicenter phase II neoadjuvant trial of lapatinib, trastuzumab, with or without endocrine therapy for 12 weeks vs. 24 weeks in patients with HER2 overexpressing breast cancer. Rimawi, M.F., Niravath, P.A., Wang, T., Rexer, B., (eds.) Proc of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium 2014 Cancer Res, vol. 75, 2015 (9 Suppl):Abstract nr S6–02.